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Abstract 24 
Interferon Regulatory Factor family members impart cell-type specificity to TLR signalling, and we 25 
recently identified a role for IRF6 in TLR2 signalling in epithelial cells. TLR3 has a well-characterized 26 
role in wound healing in the skin, and here we examined TLR3-dependent IRF6 functions in human 27 
keratinocytes. Primary keratinocytes responded robustly to the TLR3 agonist poly(IC) with upregulation 28 
of mRNAs for IFN-β, the IL-12 family member IL-23p19 and the chemokines IL-8 and CCL5. Silencing 29 
of IRF6 expression enhanced poly(IC)-inducible IFN-β mRNA levels and inhibited poly(IC)-inducible 30 
IL-23p19 mRNA expression in primary keratinocytes. Consistent with these data, co-transfection of 31 
IRF6 increased poly(IC)-inducible IL-23p19 promoter activity, but inhibited poly(IC)-inducible IFN-β 32 
promoter activity in reporter assays. Surprisingly, poly(IC) did not regulate IL-12p40 expression in 33 
keratinocytes, suggesting that TLR3-inducible IL-23p19 may have an IL-23-independent function in 34 
these cells. The only other IL-12 family member that was strongly poly(IC)-inducible was EBI3, which 35 
has not been shown to heterodimerize with IL-23p19. Both co-immunoprecipitation and proximity 36 
ligation assays revealed that IL-23p19 and EBI3 interact in cells. Co-expression of IL-23p19 and EBI3, 37 
as compared to IL-23p19 alone, resulted in increased levels of secreted IL-23p19, implying a functional 38 
role for this heterodimer. In summary, we report that IRF6 regulates a sub-set of TLR3 responses in 39 
human keratinocytes, including the production of a novel IL-12 family heterodimer (p19/EBI3). We 40 
propose that the TLR3-IRF6-p19/EBI3 axis may regulate keratinocyte and/or immune cell functions in 41 
the context of cell damage and wound healing in the skin. 42 
  43 
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Introduction 44 
Human skin maintains barrier defence by detecting and responding to microbial challenge, and by 45 
initiating repair mechanisms upon tissue damage caused by UV radiation and/or wounding. 46 
Keratinocytes use pattern recognition receptors (PRRs) to recognize and respond to microbe-47 
associated molecular patterns from microorganisms, and damage-associated molecular patterns 48 
(DAMPs) such as intracellular host factors released from damaged cells upon UV-radiation.1, 2 The 49 
toll-like receptor (TLR) family of PRRs recognize specific ligands through luminal domain-50 
containing leucine-rich repeats, thus enabling signal transduction through a cytoplasmic 51 
Toll/Interleukin-1 Receptor (TIR) domain.3 These PRRs are widely studied in responses of innate 52 
immune cells such as macrophages and dendritic cells (DCs) to microbial products. Nonetheless, 53 
epithelial cells,4 including keratinocytes,5 also express TLRs and respond to specific DAMPs.  54 
TLR signalling involves the recruitment of specific adaptor proteins, such as myeloid differentiation 55 
primary response gene 88 (MyD88) or TIR-domain-containing adapter-inducing interferon-β 56 
(TRIF), to the TIR domain of the TLR to initiate signalling.3 MyD88-dependent signalling initiates 57 
downstream signalling via IL-1R-associated kinases 4 and 1 and tumor necrosis factor associated 58 
factor-6,3 ultimately culminating in activation of MAPK p38 and JNK, and nuclear factor kappa B 59 
(NF-κB).3 NF-κB and other TLR-activated transcription factors then drive inducible expression of 60 
pro-inflammatory target genes.3 The TRIF pathway leads to activation of the serine/threonine 61 
kinase TANK-binding kinase 1, which interacts with, and phosphorylates, interferon regulatory 62 
factor 3 (IRF3).3 Activated IRF3 drives expression of type I interferons such as IFN-β.6 63 
Along with IRF3, certain other IRF family members are required for pathogen-inducible expression 64 
of type I IFN and interferon-inducible genes.6 These transcription factors impart both signalling and 65 
cell-type specificity to individual TLR pathways. For example, IRF1, IRF3, IRF5, IRF7 and IRF8 66 
have all been linked to responses downstream of individual TLRs,6 whilst IRF7 and IRF1 drive cell 67 
type-specific type I IFN production in plasmacytoid DCs7 and conventional DCs,8 respectively. 68 
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Thus, the expression patterns of individual IRF family members can determine how a specific cell 69 
type responds to TLR activation. Apart from IFN-β transcription, IRFs also regulate expression of 70 
some chemokines, such as Chemokine (C-C motif) ligand (CCL) 5 (CCL5),9 and the IL-12 family 71 
of cytokines that control differentiation of T helper (Th) cell sub-sets.10 72 
IRF6 has an important role in epidermal development in humans and in mice. It was first identified 73 
as the defective gene in Van der Woude syndrome and popliteal pterygium syndrome, the most 74 
common forms of syndromic orofacial clefting.11 Genetic variants of IRF6 are associated with 75 
various degrees of cleft lip, cleft palate, undifferentiated skin and syndactyly in humans.11, 12 76 
Subsequent studies demonstrated that IRF6 is primarily expressed in epithelial cells of various 77 
tissues in mouse, chicken, zebrafish and Xenopus laevis embryos.13, 14 IRF6 null mice show severe 78 
abnormalities in skin, limb and craniofacial development and die shortly after birth.15, 16 79 
Keratinocyte development is also dysregulated in IRF6 null mice; suprabasal keratinocytes 80 
proliferate and fail to terminally differentiate into the different layers of the epidermis.15, 16 In 81 
addition to these developmental roles, we recently demonstrated a role for IRF6 in TLR2-dependent 82 
CCL5 production in the oral epithelial cell-line OKF6,17 thus revealing a new role for this 83 
transcription factor in TLR signalling and host defence.  84 
In human keratinocytes, TLR3 has an important role in detecting DAMPs released from damaged 85 
cells,1 for example UV-damaged U1 non-coding RNA.2 There is also evidence that TLR3 plays a 86 
role in responses during physical injury. TLR3 mRNA and protein was upregulated in wounded 87 
skin and was required for TNF-α and IL-6 production at wound edges.1, 18 Furthermore, Tlr3-/- mice 88 
showed delayed wound closure and impaired expression of skin repair and tight junction genes.18, 19 89 
Tlr3 deficiency also resulted in decreased chemokine secretion, leading to defective recruitment of 90 
neutrophils and macrophages to the site of injury.18, 20 Finally, TLR3 signalling upregulated the 91 
expression of several genes associated with the maintenance of epidermal structure.21 Collectively, 92 
these data indicate that TLR3 has a critical role in detecting cell damage and initiating cell repair 93 
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processes. Given the importance of TLR3 signalling in keratinocyte responses to UV damage and in 94 
wound repair, as well as our recent identification of a role for IRF6 in TLR signalling in epithelial 95 
cells, herein we investigated the involvement of IRF6 in TLR3 responses in human keratinocytes. In 96 
so doing, we identify a TLR3-IRF6 axis that selectively drives IL-23p19 expression, and provide 97 
evidence for the existence of an IL-23-independent function for IL-23p19. 98 
  99 
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Results 100 
IRF6 is highly expressed in human keratinocytes 101 
We began by assessing IRF6 expression in a panel of human epithelial cell-lines. For comparison, 102 
gene expression was also analyzed in human monocytic cells (THP-1 cells) and macrophage-like 103 
cells (PMA-differentiated THP-1 cells), which express other IRF family members, but not IRF6.10, 104 
17 IRF6 mRNA was very highly expressed in the HaCaT keratinocyte cell-line and was moderately 105 
expressed in the CaCo-2 colon cancer cell-line. It was present at low to undetectable levels in the 106 
other epithelial cell-lines, and was also undetectable in THP-1 cells (Figure 1a). Similarly, IRF6 107 
mRNA was highly expressed in primary human keratinocytes, but not primary monocytes or 108 
macrophages (Figure 1b). In contrast, IRF3 mRNA was present in all cell populations examined and 109 
IRF8 mRNA expression was largely restricted to primary monocytes and macrophages, and 110 
monocyte/macrophage-like THP-1 cells (Figures 1a and b). IRF6 protein was expressed in the 111 
keratinocyte populations (primary keratinocytes and HaCaT cells), but was absent from CaCo-2 112 
cells (Figure 1c). Thus, consistent with the phenotypes resulting from IRF6 mutation or deficiency 113 
in different species,11, 13-16 IRF6 expression was enriched in keratinocytes in humans.  114 
Human keratinocytes respond to the TLR3 ligand poly(IC) 115 
Given recent literature linking TLR3 signalling to damage detection and wound repair,1, 2, 18, 19, 21 we 116 
initially profiled responses of keratinocytes to TLR3 versus other TLR agonists. IL-8/CXCL8 was 117 
initially examined, since this neutrophil-attracting CXC chemokine is secreted by epithelial cells in 118 
response to inflammatory stimuli.22, 23 The TLR3 agonist poly(IC) triggered robust IL-8 production 119 
in primary human keratinocytes (Figures 2a and b) and HaCaT cells (Supp. Figure S1a), as assessed 120 
by ELISA and qPCR. Responses to other TLR agonists were weak or absent. We also assessed 121 
mRNA expression of candidate TLR-inducible IRF6 target genes including IFN-β and IL-12 122 
cytokine family members (IL-12p40, IL-12p35, IL-23p19, EBI3 and IL-27p28). CCL5/RANTES was 123 
also examined because we demonstrated that IRF6 promotes TLR2-dependent CCL5 gene 124 
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expression.17 Poly(IC) stimulation up-regulated mRNA expression of IFN-β (>10,000 fold), CCL5 125 
(>10,000 fold), IL-23p19 (>40 fold) and EBI3 (>100 fold) (Figures 2c-f). In contrast to IL-23p19 126 
and EBI3 expression, mRNA levels of other IL-12 family members were either not affected (IL-127 
12p40, IL-27p28) or only marginally upregulated (IL-12p35) by poly(IC) treatment (Figures 2g-i). 128 
Again, agonists of other TLRs examined had no or modest effects on regulated gene expression in 129 
primary human keratinocytes (Figure 2) or HaCaT cells (Supp. Figure S1). 130 
IRF6 regulates a sub-set of TLR3-inducible inflammatory genes in primary keratinocytes 131 
We next used siRNA-mediated gene silencing of IRF6 (Figures 3a and b) to determine causal roles 132 
in regulating TLR3 responses in primary keratinocytes. Since IRF3 drives TLR3-inducible IFN-β 133 
expression in many cell types,6 we also silenced IRF3 expression in these cells (Figure 3c). As 134 
expected, IRF3 knock-down diminished poly(IC)-inducible IFN-β mRNA expression in primary 135 
keratinocytes (Figure 3d). Conversely, IRF6 knock-down significantly enhanced inducible IFN-β 136 
expression (Figure 3d), indicating that IRF6 negatively regulates this response. Furthermore, 137 
knockdown of IRF6, but not IRF3, significantly reduced poly(IC)-inducible IL-23p19 mRNA 138 
expression (Figure 3e). Regulated expression of EBI3 and CCL5 mRNAs was not significantly 139 
affected by either IRF6 or IRF3 knock-down (Figures 3f-g). The effects of IRF6 silencing on 140 
regulated IFN-β and IL-23p19 mRNA expression were apparent with independent siRNAs (Supp. 141 
Figure S2). As a complementary approach, we next examined the effect of IRF6 overexpression on 142 
the TLR3-regulated expression of the IFN-β and IL-23p19 promoters. To do so, we used 143 
RAW264.7 macrophages, since these cells are poly(IC)-responsive and do not express IRF6. IRF6 144 
co-transfection enhanced the poly(IC)-inducible activity of a human IL-23p19 promoter-luciferase 145 
reporter construct in these cells (Figure 3h), whereas the activity of the pGL-2C SV40 promoter-146 
luciferase reporter control was unaffected. Conversely, co-transfection with IRF6 reduced poly(IC)-147 
inducible IFN-β promoter activity in the same cells (Figure 3i). Collectively, these data indicate that 148 
IRF6 selectively promotes TLR3-inducible IL-23p19 expression, and inhibits TLR3-inducible IFN-149 
β expression. 150 
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Differentiation status differentially affects the ability of IFN-γ to prime poly(IC) responses in 151 
keratinocytes 152 
Since IRF6 regulates keratinocyte differentiation,16 we next examined IRF6 expression and TLR3 153 
responses in proliferating versus differentiated primary keratinocytes. To do so, keratinocytes were 154 
cultured in media containing the Rho-associated protein kinase inhibitor Y27632, which increases 155 
keratinocyte proliferation and prevents terminal differentiation,24 CaCl2 that promotes keratinocyte 156 
differentiation,25 or standard media (as per previous experiments). As compared to standard culture 157 
conditions, IRF6 protein levels were increased in differentiated keratinocytes and decreased in 158 
proliferating cells (Figure 4a). Consistent with this, mRNA levels of IRF6 (Figure 4b) and the 159 
keratinocyte differentiation marker involucrin (IVL)26 (Figure 4c) were significantly higher in Ca2+-160 
treated than in Y27632-treated keratinocytes. Although there were no significant differences in 161 
TLR3 responses in differentiated versus proliferating keratinocytes, differentiation status skewed 162 
poly(IC)-inducible expression of IRF6 target genes in IFN-γ-primed keratinocytes (Figures 4d-f). 163 
That is, in IFN-γ-primed keratinocytes, poly(IC)-inducible IFN-β gene expression in proliferating 164 
keratinocytes that express low levels of IRF6 was enhanced by comparison to differentiated 165 
keratinocytes that express high levels of IRF6 (Figure 4d). Conversely, the reverse was true for IL-166 
23p19 mRNA expression (Figure 4e). Regulated expression of CCL5, which was not controlled by 167 
IRF6 (Figure 3g), was unaffected by poly(IC)-stimulation in IFN-γ-primed proliferating versus 168 
differentiated keratinocytes (Figure 4f). We next examined whether IFN-γ differentially regulated 169 
IRF6 expression in proliferating versus differentiated keratinocytes, since this may contribute to the 170 
ability of this cytokine to skew the regulated expression of IRF6-dependent genes. Indeed, whereas 171 
IFN-γ significantly increased IRF6 mRNA levels in differentiated (Ca2+-treated) keratinocytes, it 172 
had no effect on IRF6 expression in proliferating (Y27632-treated) keratinocytes (Figure 4g). Thus, 173 
IFN-γ treatment accentuated the difference in IRF6 mRNA expression between differentiated and 174 
proliferating keratinocytes. These findings are again consistent with positive and negative 175 
regulation of poly(IC)-inducible IL-23p19 and IFN-β mRNA expression, respectively, by IRF6. 176 
9 
 
IL-23p19 and EBI3 interact in cells 177 
A surprising observation from our studies was that poly(IC) selectively upregulated IL-23p19 and 178 
EBI3 mRNAs in keratinocytes, without having pronounced effects on other IL-12 family members. 179 
Members of the IL-12 family of cytokines form by heterodimerization of α (p19, p28, p35) and β 180 
(p40, EBI3) sub-units,27 but an interaction between IL-23p19 (α sub-unit) and EBI3 (β sub-unit) has 181 
not previously been demonstrated. In co-immunoprecipitation studies using FLAG-tagged IL-23p19 182 
and V5-tagged EBI3 in HEK293 cells, EBI3 was recovered with immunoprecipitated IL-23p19 183 
(Figure 5a). As expected, V5-tagged IL-12p40 was also pulled down with immunoprecipitated IL-184 
23p19 (IL-23 positive control), whereas an unrelated protein (V5-tagged HDAC7) was not. A direct 185 
interaction between IL-23p19 and EBI3 in cells was confirmed using proximity ligation assays 186 
(PLA) in transfected HEK293 cells (Figure 5b). An interaction between IL-23p19 and IL-12p40 187 
again served as a positive control (IL-23 heterodimer), whereas IL-23p19-FLAG again did not 188 
interact with a control protein (HDAC7-V5). Thus, IL-23p19 and EBI3 interact to form a 189 
heterodimer in cells that co-express these IL-12 family sub-units. Finally, we asked whether co-190 
expression of IL-23p19 and EBI3 alter their cellular distribution patterns. Upon transfection of 191 
expression constructs into HEK293T cells, IL-23p19 alone was secreted at very low levels, and co-192 
transfection with EBI3 modestly enhanced levels of the IL-23p19 sub-unit in culture supernatants  193 
(Figure 5c). Further analysis confirmed the selective capacity of co-transfected EBI3-V5, but not a 194 
V5-tagged control protein of similar size to EBI3, to promote IL-23p19 secretion from HEK293T 195 
cells (Figure 5d). Collectively, these data suggest that co-expression of EBI3 and IL-23p19 results 196 
in the formation of an EBI3/IL-23p19 heterodimer, which permits secretion of IL-23p19. 197 
  198 
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Discussion 199 
We previously showed that IRF6 promotes TLR2-inducible, MyD88-dependent CCL5 expression in 200 
the oral epithelial cell-line OKF6.17 In contrast, we found here that primary human keratinocytes 201 
and the human keratinocyte cell-line HaCaT were largely unresponsive to MyD88-dependent TLR 202 
agonists. Instead, we identified dual roles for IRF6 in regulating a sub-set of TLR3 responses in 203 
primary human keratinocytes; it inhibits poly(IC)-inducible IFN-β expression, but is required for 204 
maximal induction of IL-23p19 in response to the same stimulus. This conclusion is supported by 205 
gene knock-down studies using multiple siRNAs, promoter reporter/IRF6 co-transfection studies 206 
and analysis of keratinocyte differentiation, which results in upregulated IRF6 expression and 207 
correspondingly skewed regulation of poly(IC)-inducible expression of IRF6 target genes. Another 208 
study reported that poly(IC) triggers IRF6 nuclear translocation in MCF-10A cells,28 thus further 209 
supporting a role for IRF6 in TLR3 responses in epithelial cells. We found that IRF6 localises to 210 
both the cytoplasm and nucleus in primary keratinocytes, and that poly(IC) did not trigger obvious 211 
nuclear translocation in these cells (data not shown). This may reflect dynamic regulation of the 212 
sub-cellular pools of IRF6 in keratinocytes, as we have previously observed in other cellular 213 
systems,17 or that TLR3 signalling is relayed to nuclear IRF6 to enable regulated gene expression. 214 
Several studies have examined TLR responsiveness in human keratinocytes,5, 23, 29 but the majority 215 
of these studies investigated a limited number of TLR agonists. Keratinocytes are reported to 216 
produce IL-8 upon poly(IC), zymosan, flagellin, Pam3Cys, CpG-DNA and LPS stimulation.23, 29 217 
Many of these agonists did not have pronounced effects on the expression of genes analysed in our 218 
experiments, which assessed both primary keratinocytes and HaCaT cells. The reasons for these 219 
differences are unclear. However, our findings that keratinocytes were highly sensitive to the 220 
synthetic dsRNA analogue poly(IC), which drives TLR3-dependent signalling, are generally 221 
consistent with previous literature,23, 29 and are of particular interest in light of the extensive 222 
literature linking TLR3 signalling to wound healing and cell repair in keratinocytes.1, 18, 19 223 
Interestingly, IRF6 mutations were found to be associated with impaired wound healing after 224 
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corrective cleft surgery in children.30 Moreover, IRF6 mRNA was upregulated in normal 225 
keratinocytes during scratch wounding.31 Our findings here suggest that the roles of TLR3 and IRF6 226 
in wound healing may be functionally connected. 227 
Our functional analysis identified two roles for IRF6 in TLR3 responses; suppression of inducible 228 
IFN-β mRNA and promotion of inducible IL-23p19 mRNA expression. The specific mechanisms 229 
responsible for these opposing effects require further investigation. For example, it is possible that 230 
IRF6 negatively regulates IFN-β mRNA expression by antagonizing IRF3 action, either through 231 
competition with IRF3 at the IFN-β promoter or through heterodimerization with IRF3. 232 
Characterization of the IL-23p19 promoter has revealed that the IL-23p19 promoter contains a 233 
putative IRF3 and IRF7 binding site within the IFN-stimulated response element.32 Subsequently, 234 
IRF3 was shown to bind the IL-23p19 promoter, and enhance its activation.32, 33 Our analysis has 235 
now shown that IRF6 also positively regulates the IL-23p19 promoter. Interestingly, the pro-236 
inflammatory cytokine IFN-γ skewed poly(IC)-inducible expression of these two IRF6-target genes 237 
in proliferating versus differentiated keratinocytes. IRF family members play essential roles in IFN-238 
γ signalling. Immediate IFN-γ-inducible gene expression is controlled by the IFN-stimulated gene 239 
factor 3, a complex of IRF9 and STAT family members.34 Moreover, a second round of IFN-γ 240 
signalling is driven by inducible expression of IRF1.34 Other IRF family members, including IRF735 241 
and IRF8,36 also have roles in IFN-γ responses. We found that IFN-γ treatment selectively increased 242 
IRF6 mRNA expression in differentiated keratinocytes. Thus, the most likely explanation for our 243 
findings with proliferating versus differentiated keratinocytes is that the elevated IRF6 expression in 244 
IFN-γ-primed differentiated keratinocytes inhibits and enhances poly(IC)-inducible IFN-β and IL-245 
23p19 mRNA expression, respectively. Whether IFN-γ also regulates IRF6 function (e.g. through 246 
post-translational modification) or enables synergistic interactions with other IRF family members 247 
is yet unknown. Consistent with our findings, IFN-γ has previously been shown to promote the 248 
expression of the keratinocyte differentiation markers IVL, transglutaminase type 1 and cornifin.37, 249 
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38 Thus, IFN-γ may itself provide a differentiation signal to keratinocytes, further increasing IRF6 250 
expression and its effects in regulating specific TLR3 target genes. Interestingly, a recent study 251 
showed that IFN-γ and poly(IC) synergized for enhanced anti-viral responses against herpes 252 
simplex virus type-1 in human keratinocytes.39 Thus, it is possible that IFN-γ-mediated upregulation 253 
of IRF6 expression and subsequent shaping of TLR3 responses may also contribute to anti-viral 254 
responses in keratinocytes. 255 
As an important regulator of Th17 responses,27 IL-23 contributes to pathological pro-inflammatory 256 
responses in the skin, for example psoriasis.40 Genetic studies have also linked variation in the IL-257 
23p19, IL-12B and IL-23R genes with psoriasis.41 Consequently, the targeting of IL-23 is being 258 
pursued as a therapy for such conditions.42 Dermal DCs have been reported to secrete IL-23,43 259 
however we were unable to detect TLR3-inducible IL-12p40 expression in keratinocytes in this 260 
study. Whatever the cellular source of IL-23, existing literature indicates that the IL-23/IL-17 axis 261 
has a negative impact on wound healing. For example, IL-17 produced by inflammatory infiltrates 262 
after wounding caused a delay in wound closure, whilst an anti-IL-17 blocking antibody restored 263 
wound closure.44 Similarly, wound healing was accelerated in Il-17-/- mice44 and in Il-12p40-/- 264 
mice.45 Consistent with our observation of selective poly(IC)-inducible IL-23p19 mRNA expression 265 
in keratinocytes, IL-23p19 was also reported to be selectively upregulated in UV-damaged 266 
keratinocytes.46 Another study in intestinal epithelial cells, using both in vivo and in vitro systems, 267 
also showed that the pro-inflammatory mediators IL-1α and TNF-α up-regulated IL-12p35, IL-268 
23p19 and EBI3 expression, but not IL-12p40.47 Such evidence suggests that, in epithelial cells 269 
responding to inflammatory signals, IL-23p19 may have a distinct role to the IL-23p19/p40 270 
heterodimer. 271 
IL-12 and IL-23 are formed intracellularly by the heterodimerization of the p35 and p40 or p19 and 272 
p40 sub-units, respectively, and are secreted as functional heterodimers.27 Our observations that IL-273 
23p19 (α sub-unit) and EBI3 (β sub-unit) interact in cells, and that co-expression of IL-23p19 and 274 
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EBI3 increased the secretion of IL-23p19, suggests that co-expression of these two sub-units is 275 
likely to have functional consequences. Whether this involves the action of a novel IL-12 cytokine 276 
family member (IL-23p19/EBI3) or whether EBI3 instead regulates the stability and/or secretion of 277 
IL-23p19 monomers in keratinocytes remains to be determined. Transfected HEK293T cells 278 
secreted much lower levels of IL-23p19 when co-transfected with EBI3 as compared to IL-12p40. 279 
A recent study showed that, in contrast to IL-12 (IL-12p35/IL-12p40), IL-35 (IL-12p35/EBI3) was 280 
also not efficiently secreted from cells.48 This suggests that additional signals may be required for 281 
the efficient secretion of some members of this cytokine family, particularly EBI3-containing 282 
cytokines. It is also possible that the IL-23p19/EBI3 heterodimer may function as an alarmin that is 283 
released from damaged cells. EBI3-containing cytokines of the IL-12 cytokine family (IL-27 and 284 
IL-35) generally have immunosuppressive functions.27 It therefore seems likely that, upon TLR3-285 
mediated keratinocyte activation, co-expression of IL-23p19 and EBI3 may contribute to wound 286 
healing by dampening inflammatory responses. This theory awaits functional evidence. 287 
In humans, IRF6 expression has been reported in oral, epidermal and mammary epithelial cells.49-51 288 
The finding that IRF6 expression was particularly elevated in keratinocytes is consistent with 289 
findings from mouse models,15, 16 and the phenotypic effects of IRF6 deficiency in humans.11 One 290 
interesting observation from our expression analysis was that IRF6 mRNA and protein expression 291 
did not always track. Although primary keratinocytes and HaCaT cells expressed high levels of this 292 
transcription factor at the mRNA and protein level, T24 and CaCo-2 cells expressed IRF6 mRNA, 293 
whereas IRF6 protein expression was not detectable by immunoblotting. Previous studies have 294 
shown that loss of IRF6 expression results in more invasive squamous cell carcinomas.52 Cell 295 
proliferation leads to IRF6 phosphorylation, and subsequently results in its proteosomal 296 
degradation.51 This may contribute to the loss of IRF6 expression in aggressive tumours.52 Hence, it 297 
is possible that loss of IRF6 protein expression may contribute to the transformation and/or 298 
metastatic potential of other epithelial cancer cells, such as CaCo-2 and T24 cells that were 299 
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examined in this study. Hence, future studies should examine IRF6 expression and TLR3-dependent 300 
functions in other primary epithelial cells, for example respiratory and intestinal epithelial cells.  301 
In summary, we have demonstrated that IRF6 selectively regulates a sub-set of TLR3 responses in 302 
keratinocytes, that keratinocytes respond to TLR3 activation with a unique profile of IL-12 family 303 
member expression, that the TLR3-inducible IL-12 family members IL-23p19 and EBI3 interact in 304 
cells, and that co-expression of EBI3 with IL-23p19 increases extracellular levels of IL-23p19. 305 
Given the essential role of TLR3 signalling in wound healing,1, 2 the selective upregulation of IL-306 
23p19 and EBI3, the former in an IRF6-dependent manner, may contribute to this process. Future 307 
studies should focus on elucidating the contribution of IRF6 and IL-23p19/EBI3 to wound healing 308 
and host defence, as well as determining whether this pathway is active in other epithelial tissues. 309 
Methods 310 
Cells and cell-lines used were primary epidermal keratinocytes, human monocytes and monocyte-311 
derived macrophages, A498, CaCo-2, HeLa, T24, HaCaT, BEAS-2B, HEK293, HEK293T, MCF-7 312 
and THP-1. Full details of cell culture, reagents, and treatments with different stimuli are provided 313 
in SI Materials and Methods, as are details on RNA preparation and qPCR, immunoblotting, 314 
plasmid constructs, gene reporter assays, co-immunoprecipitation experiments, immunoblotting for 315 
IL-12 family member expression and secretion, gene knock-down, ELISA, PLA and statistical 316 
analyses.   317 
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Figure Legends 476 
Figure 1. Human keratinocytes express high levels of IRF6. mRNA levels of IRF6, IRF3 and 477 
IRF8, relative to HPRT, were examined by qPCR in the indicated (A) epithelial and myeloid cell-478 
lines and (B) primary cells. Data represents mean ± SEM of 3 independent experiments, ** p < 479 
0.01, *** p ≤ 0.001, ****p≤ 0.0001 (compared to all other cell populations; one-way ANOVA, 480 
followed by Tukey’s test), ND indicates that mRNA expression was not detected in the sample. (C) 481 
Whole cell lysates from the indicated cell-lines were subjected to SDS PAGE and immunoblotting 482 
for IRF6 and GAPDH (loading control). Data for this experiment is representative of 3 independent 483 
experiments. 484 
Figure 2. Primary keratinocytes respond to the TLR3 agonist poly(IC). Primary keratinocytes 485 
were stimulated for the indicated times with poly(IC) (30 μg/ml), zymosan (100 µg/ml), flagellin 486 
(10 ng/ml), Pam3Cys (15 ng/ml), CpG 2006 (0.3 µM), LPS (100 ng/ml) or were left untreated, after 487 
which (A) levels of secreted IL-8 were quantified by ELISA or mRNA levels of (B) IL-8, (C) IFN-488 
β, (D) CCL5, (E) IL-23p19, (F) EBI3, (G) IL-12p40, (H) IL-12p35 and (I) IL-27p28 were 489 
quantified, relative to HPRT, using qPCR. Data represents mean ± SEM from 3 independent 490 
experiments. * p ≤ 0.05, ** p < 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 as compared to the 491 
unstimulated control (two-way ANOVA, followed by Tukey’s test). 492 
Figure 3. IRF6 promotes TLR3-inducible IL-23p19 expression, but inhibits TLR3-inducible 493 
IFN-β mRNA expression. IRF6 and IRF3 expression in primary human keratinocytes were 494 
silenced by transfection with specific siRNAs. After 72 h, cells were stimulated with poly(IC) (30 495 
µg/mL) for 4 h or were left unstimulated, after which total cellular RNA and whole cell lysates 496 
were obtained. Basal levels of IRF6 mRNA (A), IRF6 and GAPDH (loading control) protein (B), as 497 
well as IRF3 mRNA levels (C) were determined by qPCR or immunoblotting. Poly(IC)-inducible 498 
levels of mRNAs for (D) IFN-β, (E) IL-23p19, (F) EBI3 and (G) CCL5 were quantified by qPCR. 499 
mRNA levels were quantified relative to HPRT, and are displayed relative to the poly(IC)-500 
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stimulated no siRNA control. Data represents mean ± SEM from 6 independent experiments, except 501 
for (B) that is representative of 2 independent experiments. * p < 0.05, ** p < 0.01, as compared to 502 
the other siRNA transfected cells (A and C) (one-way ANOVA, followed by Tukey’s test), or 503 
poly(IC)-treated cells (D-G) (two-way ANOVA, followed by Tukey’s test). RAW264.7 cells were 504 
transfected with 5 μg IRF6 plasmid or empty vector, as well as (H) 5 μg pGL2C or IL-23p19-luc or 505 
(I) 5 μg pGL2B or IFN-β-luc. After 21 h, cells were stimulated with poly(IC) (30 µg/ml) for 8 h, or 506 
were left untreated. Lysates were prepared and luciferase activity was quantified, relative to total 507 
protein. Data represents mean ± SEM of three independent experiments. * p < 0.05, as compared to 508 
poly(IC)-stimulated empty vector control (two-way ANOVA, followed by Tukey’s test). 509 
Figure 4. Differentiation status of keratinocytes affects IRF6 expression, as well as regulated 510 
expression of poly(IC)-inducible IRF6 target genes. (A) Whole cell lysates from proliferating 511 
and differentiated keratinocytes were subjected to SDS PAGE, and immunoblotting for IRF6 and 512 
GAPDH (loading control) was performed. Similar results were apparent in 3 independent 513 
experiments. Levels of IRF6 (B) and IVL (C) mRNAs (relative to HPRT) in proliferating (Y27632-514 
treated; 5 µM for 24 h) and differentiated (Ca2+-treated; 2 mM for 24 h) primary keratinocytes were 515 
determined by qPCR. Data represents mean ± SEM of 3 independent experiments, * p < 0.05, ** p 516 
< 0.01 (one-way ANOVA, followed by Tukey’s test). Proliferating (Y27632-treated; 5 μM for 24 h) 517 
and differentiated (Ca2+-treated; 2 mM for 24 h) primary keratinocytes were primed with IFN-γ (2.5 518 
ng/ml) or were left untreated for 24 h, after which they were stimulated with poly(IC) (30 μg/ml) 519 
for 4 h. Total RNA was collected and mRNA levels of (D) IFN-β, (E) IL-23p19 and (F) CCL5 were 520 
quantified, relative to HPRT, using qPCR. (G) Levels of IRF6 mRNA (relative to HPRT) in 521 
proliferating (Y27632-treated; 5 µM for 24 h) and differentiated (Ca2+-treated; 2 mM for 24 h) 522 
primary keratinocytes, treated with or without IFN-γ (2.5 ng/ml) for 24 h, were determined by 523 
qPCR. Data represents mean ± SEM of 3 independent experiments, * p < 0.05, ** p < 0.01 (two-524 
way ANOVA, followed by Tukey’s test).  525 
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Figure 5. IL-23p19 and EBI3 interact in cells. (A) HEK293 cells were transfected with a FLAG-526 
tagged IL-23p19 plasmid and V5-tagged IL-23p19, EBI3, IL-12p40 or HDAC7 plasmids, after 527 
which cell extracts were immunoprecipitated with an anti-FLAG antibody followed by 528 
immunoblotting with anti-FLAG and anti-V5 antibodies. Data are representative of 4 independent 529 
experiments. (B) HEK293 cells were transfected with 4 ng IL-23p19-FLAG plasmid plus 4 ng of 530 
EBI3-V5, IL-12p40-V5 or HDAC7-V5 plasmids. Proximity ligation assays were then performed, 531 
with the signal detected by confocal microscopy. Data are representative of 2 independent 532 
experiments. (C) HEK293T cells were transfected with the indicated plasmids, and after 48 h, cell 533 
culture supernatants were collected and cell lysates were prepared. Levels of V5-tagged proteins in 534 
cell culture supernatants and GAPDH in cell lysates were detected by immunoblotting. Data are 535 
representative of 3 independent experiments. (D) HEK293T cells were transfected as in (C), and 536 
levels of IL-23p19 in cell culture supernatants were determined by immunoblotting and subsequent 537 
quantification (relative to GAPDH in cell lysates). The control plasmid used was RNF144B-V5. 538 
Data represents mean ± SD of 3 independent experiments, * p < 0.05 (one-way ANOVA, followed 539 
by Tukey’s test), ND indicates that protein expression was not detected in the sample. 540 
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